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Abstract 
Review on t(2;11)(p21;q24), with data on clinics, 
and the genes involved. 
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Clinics and pathology 
Disease 
Chronic and acute myeloid malignancies 
Phenotype/cell stem origin 
1 acute promyelocytic leukemia (APL) (Prigogina 
et al., 1986), 1 acute myeloid leukemia with 
maturation  (AML-M2) that developed after a short 
period of myelodysplastic syndrome (Testoni et al., 
1989), 1 refractory cytopenia with multilineage 
dysplasia (RCMD) (Thorsen et al., 2012) and 1 
myelodysplastic/myeloproliferative neoplasm 
(MPN), unclassifiable (McCormick et al., 2014). 
Epidemiology 
3 males and 1 female aged 34, 52, 54 and 65 years. 
Prognosis 
The patient with M2-AML reached a complete 
remission after chemotherapy (Testoni et al, 1989). 
The patient with RCMD received treatment with 
lenalidomide and 6 months later presented with a 
complete hematological and major cytogenetic 
response, followed by cytogenetic relapse but with 
no signs of transformation without therapy 3+ years 
from the diagnosis (Thorsen et al., 2012). Similarly,  
the patient with a clinically stable polycythemia 
vera-like myeloid neoplasm requires only periodic 
phlebotomies 70 months after diagnosis 
(McCormick et al., 2014). These data suggests that 
t(2:11)(p21;q24) may occur in patients with a 
clinically indolent myeloproliferative disorder. 
Cytogenetics 
Cytogenetics morphological 
Because of difficulties to determine terminal 11q 
chromosome breakpoints and because of the similar 
cytogenetic appearance of translocations 
t(2;11)(p21;q24) and the more common 
t(2;11)(p21;q23) that has been described with or 
t(2;11)(p21;q23) without MLL ( KMT2A) 
involvement, FISH is recommended to exclude 
11q23/MLL rearrangements. 
Additional anomalies 
Found in association with 5q deletions in 3 out of 4 
patients: in AML-M2 (Testoni et al., 1989), RCMD 
(Thorsen et al., 2012) and in the MPN patient 
(McCormick et al., 2014).  
The later was found to carry a mutation in exon 12 
of JAK2 with two clonally-related abnormal cell 
lines with t(2;11)(p21;q23-24) and 11q breakpoints 
near a miR-125b-1 locus at 11q24. One of this 
clones had the t(2;11)(p21;q23-24) as a sole 
anomaly, the other had del(5)(q15q31) in a side-line 
and a third abnormal clone showed del(5q)(q13q31) 
as a sole abnormality, with breakpoints distinct 
from the t(2;11)-associated del(5q) clone. Found 
with +19 and non-recurring abnormalities in the 
APL patient (Prigogina et al., 1986). 
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Figure 1. Partial karyotypes showing rearrangement between chromosomes 2 and 11 (A). Fluorescence in situ hybridization with 
LSI MLL (KMT2A) and LSI MYCN break-apart probes (Abott Molecular/Vysis, US) showing normal MLL signals on chromosome 
11 and der(11) and translocation of MYCN located on 2p24 telomeric to MLL gene (B). 
 
Genes involved and 
proteins 
MIR125B1 (microRNA 125b-1) 
Location 
11q24.1 
DNA/RNA 
Description microRNAs (miRNAs) are short non-
coding RNAs of about 19-22 nucleotides in length 
that play a role in post-transcriptional regulation of 
gene expression by affecting both the stability and 
translation of mRNAs.  miRNAs have multiple 
functions including regulation of cellular 
proliferation, differentiation, and cell death. 
MIR125B1 has found to play a role in regulation of 
normal haematopoiesis (Thorsen et al., 2012; 
McCormick et al., 2014). 
Result of the chromosomal 
anomaly 
Fusion protein 
Oncogenesis 
The chromosomal translocation t(2;11)(p21;q24) 
has been described in myeloid neoplasias, 
suggesting its involvement in deregulation of genes 
relevant in myeloid cell transformation. 
t(2;11)(p21;q24) is accompanied by other 
anomalies, particularly with deletion of the long 
arm of chromosome 5 that is also characteristic of 
myeloid malignancies, therefore probably 
representing a secondary abnormality in these 
patients. The translocation breakpoint in 
t(2;11)(p21;q24) had been mapped close to 
microRNA locus, MIR125B1 at 11q24 that have 
been suggested to be pathogenetically involved  
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(Bousquet et al., 2010; Thorsen et al., 2012; 
McCormick et al., 2014).  According to these recent 
reports, this translocation has not been found to 
lead to gene fusion but is associated with 
deregulation of MIR125B1, supporting its 
pathogenetic role in oncogenesis. MIR125B1 is a 
regulator of normal hematopoiesis and its 
overexpression has been found to target several 
genes (STAT3, BAK1, JUN, JUND, and LIN28A) 
capable of modulating hematopoietic development 
(Bousquet et al., 2010).  Dysregulated MIR125B1 
may promote leukaemogenesis by arresting 
myeloid and monocytic differentiation, promoting 
stem cell renewal and targeting multiple factors in 
the TP53 pathway (Bousquet et al., 2010; 
McCormick et al., 2014). In addition to increased 
expression of MIR125B1 in patients with a 
t(2;11)(p21;q24), it is also possible  and that disease 
pathogenesis may be influenced by other concurrent 
aberrations, such as 5q deletions and JAK2 
mutations that may act in a concurrent or 
synergistic way. 
Note also the existence of a t(11;14)(q24;q32) 
IGH/MIR125B1 
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